Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by approximately 9%, while the share price has rallied by around 40% over the same period, resulting in ...

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 03/02/2026

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 02/03/2026

Kinepolis Group Lower results, as expected, impacted by less visitors but higher dividend

Against the backdrop of ongoing restructuring and recapitalization in Hollywood, Kinepolis received in FY25 -5.8% y/y visitors or 30.7m, down. Kinepolis Group indicated that -although 2025 saw some notable successes- mainly in the animation and horror genres, the year was affected by a less favourable comparison base, partly due to the exceptional success of 'Inside Out 2' and several French films in 2024. We maintain our positive stance (Buy, € 42 Target Price) as Kinepolis highlighted that FY26 got off to a promising start thanks to the success of some strong year-end films such as ‘Avatar...

AB InBev Pouring beer and returning cash

Whilst ABI's beer volumes have been impacted in the past three years by a mix of country-specific and broader affordability issues and possibly also a changing attitude towards alcohol consumption in some mature markets, we see green shoots and expect volume growth to resume this year, which should support investor sentiment. We still see ABI as the undisputed leader in the beer space, with leading market shares in many of the world's largest profit pools, ongoing digitization and premiumization trends allowing to generate healthy free cash flows, which we expect ABI to increasingly direct tow...

Zealand Pharma Positive phase 1a data for Kv1.3 channel blocker

Zealand Pharma reported positive phase 1a topline results for the Kv1.3 channel blocker ZP9830. Single ascending doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings, and PK/PD profile was in-line with predictions. We view these data as de-risking for the program and look forward to the MAD data expected in 2H26, which should provide insight into extended exposure and additional proof of mechanism. Given the selective expression of Kv1.3 on effector memory T cells, we believe Kv1.3 blockers have pipeline-in-a-product potential in the at...